Dual Hypocretin Receptor Antagonism Is More Effective for Sleep Promotion than Antagonism of Either Receptor Alone
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
The hypocretin (orexin) system is involved in sleep/wake regulation, and antagonists of both hypocretin receptor type 1 (HCRTR1) and/or HCRTR2 are considered to be potential hypnotic medications. It is currently unclear whether blockade of either or both receptors is more effective for promoting sleep with minimal side effects. Accordingly, we compared the properties of selective HCRTR1 (SB-408124 and SB-334867) and HCRTR2 (EMPA) antagonists with that of the dual HCRTR1/R2 antagonist almorexant in the rat. All 4 antagonists bound to their respective receptors with high affinity and selectivity in vitro. Since in vivo pharmacokinetic experiments revealed poor brain penetration for SB-408124, SB-334867 was selected for subsequent in vivo studies. When injected in the mid-active phase, SB-334867 produced small increases in rapid-eye-movement (REM) and non-REM (NR) sleep. EMPA produced a significant increase in NR only at the highest dose studied. In contrast, almorexant decreased NR latency and increased both NR and REM proportionally throughout the subsequent 6 h without rebound wakefulness. The increased NR was due to a greater number of NR bouts; NR bout duration was unchanged. At the highest dose tested (100 mg/kg), almorexant fragmented sleep architecture by increasing the number of waking and REM bouts. No evidence of cataplexy was observed. HCRTR1 occupancy by almorexant declined 4-6 h post-administration while HCRTR2 occupancy was still elevated after 12 h, revealing a complex relationship between occupancy of HCRT receptors and sleep promotion. We conclude that dual HCRTR1/R2 blockade is more effective in promoting sleep than blockade of either HCRTR alone. In contrast to GABA receptor agonists which induce sleep by generalized inhibition, HCRTR antagonists seem to facilitate sleep by reducing waking "drive".
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sakurai, T., Amemiya, A., Ishii, M., Matsuzaki, I., Chemelli, R. M., Tanaka, H., Williams, S. C., Richardson, J. A., Kozlowski, G. P., Wilson, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)80949-6 · Cited by 5,501 · cited 1×
“Such was the case for hypocretin (orexin), whose cell bodies in the perifornical and lateral hypothalamus synthesize a pair of neuropeptides alternatively called hypocretin-1 (HCRT1) or orexin-A and hypocretin-2 (HCRT2) or orexin-B [1,2].”
The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity
de Lecea, L., Kilduff, T. S., Peyron, C., Gao, X.-B., Foye, P. E., Danielson, P. E., Fukuhara, C., Battenberg, E. L. F., Gautvik, V. T., Bartlett, F. S., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.1.322 · Cited by 3,878 · cited 2×
“SB-334867 (1-(2-methylbenzoxazol-6-yl)-3-[1,5]naphthyridin-4-yl-urea hydrochloride), zolpidem (N,N,6-Trimehtyl-2(methylphenyl)-imidazol[1,2-a]pyridine-3-acetamide) and SB408124 (1-(6,8-difluoro-2-methyl-quinolin-4-yl)-3-(4-dimethylamino-phenyl)-urea) were purchased from Tocris Bioscience (Ellisville, MO).”
MethodSelf-citationNarcolepsy in orexin Knockout Mice
Chemelli, R. M., Willie, J. T., Sinton, C. M., Elmquist, J. K., Scammell, T., Lee, C., Richardson, J. A., Williams, S. C., Xiong, Y., Kisanuki, Y., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)81973-x · Cited by 3,095 · cited 2×
“Identification of a mutation in the gene encoding HCRT receptor 2 (HCRTR2 or OX2R) as the cause of canine narcolepsy [3] and demonstration that HCRT ligand-deficient mice exhibited periods of behavioral arrest that resembled both human and canine narcolepsy [4] implicated the HCRT system in sleep/wake control well bef…”
Lin, L., Faraco, J., Li, R., Kadotani, H., Rogers, W., Lin, X., Qiu, X., de Jong, P. J., Nishino, S., & Mignot, E. (1999) · Cell · doi:10.1016/s0092-8674(00)81965-0 · Cited by 2,613 · cited 2×
“Identification of a mutation in the gene encoding HCRT receptor 2 (HCRTR2 or OX2R) as the cause of canine narcolepsy [3] and demonstration that HCRT ligand-deficient mice exhibited periods of behavioral arrest that resembled both human and canine narcolepsy [4] implicated the HCRT system in sleep/wake control well bef…”
Differential expression of orexin receptors 1 and 2 in the rat brain
Marcus, J. N., Aschkenasi, C. J., Lee, C. E., Chemelli, R. M., Saper, C. B., Yanagisawa, M., & Elmquist, J. K. (2001) · Journal of Comparative Neurology · doi:10.1002/cne.1190 · Cited by 1,659 · cited 4×
“[37] and was in good agreement with the distribution of Hcrtr2-expressing neurons previously described [42,43].”
InfluentialThe sleep switch: hypothalamic control of sleep and wakefulness
Saper, C. B., Chou, T. C., & Scammell, T. E. (2001) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)02002-6 · Cited by 1,656
A role for lateral hypothalamic orexin neurons in reward seeking
Harris, G. C., Wimmer, M., & Aston-Jones, G. (2005) · Nature · doi:10.1038/nature04071 · Cited by 1,311 · cited 1×
“Other studies have suggested roles for the HCRT system in neuroendocrine, cardiovascular, water balance, and gastrointestinal control [14], nociception and hyperalgesia [15,16,17], stress and stress-induced analgesia [18,19], reward and addiction [20,21,22,23], and panic anxiety [24].”
The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness
Sakurai, T. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2092 · Cited by 1,276 · cited 2×
“An extensive literature has since led to the conclusion that the HCRT system is wake-promoting [8,9,10,11] and involved in energy homeostasis [12,13].”
Borgland, S. L., Taha, S. A., Sarti, F., Fields, H. L., & Bonci, A. (2006) · Neuron · doi:10.1016/j.neuron.2006.01.016 · Cited by 718 · cited 1×
“Other studies have suggested roles for the HCRT system in neuroendocrine, cardiovascular, water balance, and gastrointestinal control [14], nociception and hyperalgesia [15,16,17], stress and stress-induced analgesia [18,19], reward and addiction [20,21,22,23], and panic anxiety [24].”
Fos Expression in Orexin Neurons Varies with Behavioral State
Estabrooke, I. V., McCarthy, M. T., Ko, E., Chou, T. C., Chemelli, R. M., Yanagisawa, M., Saper, C. B., & Scammell, T. E. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-05-01656.2001 · Cited by 654 · cited 1×
“By the middle of the active phase, both endogenous HCRT tone [46,47] and sleep pressure are increased, so HCRTR antagonists are more likely to be effective at this time of day than at dark onset.”
Cited by
Circadian rhythm as a therapeutic target
Ruan, W., Yuan, X., & Eltzschig, H. K. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00109-w · Cited by 486
The Neurobiology of Sleep and Wakefulness
Schwartz, M. D., & Kilduff, T. S. (2015) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2015.07.002 · Cited by 207
Self-citationThe discovery of suvorexant, the first orexin receptor drug for insomnia
Coleman, P. J., Gotter, A. L., Herring, W. J., Winrow, C. J., & Renger, J. J. (2017) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104837 · Cited by 128
Herring, W. J., Roth, T., Krystal, A. D., & Michelson, D. (2019) · Journal of Sleep Research · doi:10.1111/jsr.12782 · Cited by 53
Metadata
- Authors
- Morairty, S. R., Revel, F. G., Malherbe, P., Moreau, J.-L., Valladao, D., Wettstein, J. G., Kilduff, T. S., & Borroni, E.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-07-02
- Volume
- 7
- Issue
- 7
- Pages
- e39131
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2068471533
- Cited by
- 121
- References
- 14
- FWCI
- 8.14
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dual Hypocretin Receptor Antagonism Is More Effective for Sleep Promotion than Antagonism of Either Receptor Alone. https://app.cochat.ai/papers/10.1371/journal.pone.0039131
- The paper
- Morairty, S. R., Revel, F. G., Malherbe, P., Moreau, J.-L., Valladao, D., Wettstein, J. G., Kilduff, T. S., & Borroni, E. (2012). Dual Hypocretin Receptor Antagonism Is More Effective for Sleep Promotion than Antagonism of Either Receptor Alone. PLoS ONE. https://doi.org/10.1371/journal.pone.0039131
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.